||EPS - Basic
||Market Cap (m)
|Electronic & Electrical Equipment
Feedback Share Discussion Threads
Showing 1451 to 1473 of 1475 messages
|Good results from 2 days ago.
Bit of chat on Vox Markets - starts 42:20.
And more buying than selling.|
|Low cash but they are dealing with £2k monthly cash burn from may to October how long will that take to cover?|
|any clues as to why the spike?|
|Nice rns.. Future looking good although cash levels low|
|A little top up on today's pull back. Low risk I think. Finals last year 6th Nov.|
|Slowly moving up, low number of shares and news this month|
|FEEDBARK on the move|
|Volume picking up..should be over 2 today awaiting news|
|During the year, TexRAD has been purchased by institutions including ELK in Berlin, Velindre Cancer Centre in Cardiff, University of Tokyo Department of Radiology at the Institute of Medical Science in Japan, CHU de Reims in France and Seoul National University Bundang Hospital in South Korea, among others.|
|Might try a small top up before Oct..|
|Next news October which could be very interesting|
|Nothing goes up in straight lines this has massive potential should find its way to several pence short term|
|Yesterday biggest riser, today biggest loser|
|Some are sells...|
|craft mm tricks....the buys are looking like sells.
Done a dummy trade online and you can buy well under 2.5|
king kong dong
|Nice article in Daily Mail with chart|
|STOCK WATCH - FEEDBACK
Shares in medical imaging tool company Feedback more than doubled yesterday on a confident trading update.
One of its products is TexRAD, which allows users to look at textures in medical images.
Feedback is making progress on a way to integrate the device with scanners in UK hospitals.
It has been demonstrating a prototype to potential users and said orders had increased significantly.
Feedback said full-year results in October should show turnover significantly up on last year. Shares rose 156 per cent, or 1.3p, to 2.18p.
|There has been a focus on developing strategic collaborations for TexRAD while continuing the sales of research versions to world-leading research institutions. During the year, TexRAD has been purchased by institutions including ELK in Berlin, Velindre Cancer Centre in Cardiff, University of Tokyo Department of Radiology at the Institute of Medical Science in Japan, CHU de Reims in France and Seoul National University Bundang Hospital in South Korea, among others. The company was also delighted to announce on 9 September 2015 that TexRAD had completed its first sale to China with an installation at Peking University Medical College Hospital, Beijing. We have also worked closely with leading research groups with a view to commercialising TexRAD for specific applications. Since the year end and following the highly encouraging early results from a retrospective study into TexRAD's potential use in the treatment of urolithiasis (formation of kidney stones), the Company formed a joint venture company, Stone Checker Software Ltd ('Stone Checker'). Stone Checker will use our intellectual property in conjunction with other biomarkers to develop an integrated product to assist clinicians to determine which stones are most likely to respond to shock wave lithotripsy. We have, in the new financial year, formed another joint venture company, Prostate Checker Ltd to target a more effective method of diagnosing and assessing treatment options for prostate cancer.|
|More news October.. Very interesting.. Market cap 3m..possibly 100m in a year|
|Elucid recent not an old copy... The number of new purchase orders received for TexRAD research versions has increased significantly in recent months leading to expectations of a much improved cash inflow over the next few months.|
|I like this The Board believes the future for Feedback is hugely promising and we look forward to working closely with Alliance and developing our other collaborative ventures.|
|low on cash balance!
Interim Results for the six months ended 30 November 2015
The cash balance as at 30 November 2015 was £164,000
Collectoral cancer screening programmes are being taken nationwide, Luxembourg the latest to give it to 55-plussers.
So a new, more efficient scan technique in that field should be well received.|